Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis

Journal of Clinical Psychopharmacology

Volumn 34, Issue 3, 2014, Pages 344-349

  Brunt, Tibor M ^a,b   Van Genugten, Marianne ^c   Höner Snoeken, Kathrin ^d   Van De Velde, Marco J ^d   Niesink, Raymond J M ^a  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Ministry of Health Welfare and Sport Netherlands   (Netherlands)

Author keywords

cannabidiol; delta 9 tetrahydrocannabinol; medicinal cannabis; subjective effects; visual analog scale

Indexed keywords

CANNABIDIOL; DRONABINOL; MEDICAL CANNABIS; CANNABIS; PLANT MEDICINAL PRODUCT;

ADULT; ADVERSE DRUG REACTION; ALERTNESS; ANXIETY; ARTICLE; CANNABIS USE; CHRONIC PAIN; CROSS-SECTIONAL STUDY; DEJECTION; DISORIENTATION; DIZZINESS; FATIGUE; FEMALE; HUMAN; INCREASED APPETITE; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; NEOPLASM; PATIENT SATISFACTION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMETRY; SIDE EFFECT; SLEEP DISORDER; SOCIALIZATION; THERAPY EFFECT; TRANQUILIZING ACTIVITY; VISUAL ANALOG SCALE; AGED; CHEMISTRY; ISOLATION AND PURIFICATION; MIDDLE AGED; NETHERLANDS; PHYTOTHERAPY; QUESTIONNAIRE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CANNABIDIOL; CANNABIS; CHRONIC PAIN; CROSS-SECTIONAL STUDIES; DRONABINOL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NETHERLANDS; PATIENT SATISFACTION; PHYTOTHERAPY; PLANT PREPARATIONS; PSYCHOMETRICS; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900504430     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000129     Document Type: Article

References (48)

1. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1-25.
2. Block RI, Erwin WJ, Farinpour R, et al. Sedative, stimulant, and other subjective effects of marijuana: relationships to smoking techniques. Pharmacol Biochem Behav. 1998;59:405-412.
3. Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 2003;22:453-460.
4. Taura F, Sirikantaramas S, Shoyama Y, et al. Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa. FEBS Lett. 2007;581:2929-2934.
5. 2 receptor agonists in vitro. Br J Pharmacol. 2007;150:613-623.
6. 2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199-215.
7. Sylantyev S, Jensen TP, Ross RA, et al. Cannabinoid-and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A. 2013;110:5193-5198.
8. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry. 2001;178:107-115.
9. Large M, Sharma S, Compton MT, et al. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68:555-561.
10. Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000;57:547-552.
11. Budney AJ, Hughes JR, Moore BA, et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004;161:1967-1977.
12. Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs. 2011;25:187-201.
13. Rog DJ. Cannabis-based medicines in multiple sclerosisVa review of clinical studies. Immunobiology. 2010;215:658-672.
14. Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol. 2005;6:35-42.
15. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374:1383-1391.
16. Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515-527.
17. Horváth B, Mukhopadhyay P, Haskó G, et al. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol. 2012;180:432-442.
18. Zuardi AW, Crippa JA, Hallak JE, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des. 2012;18:5131-5140.
19. Arnold JC, Boucher AA, Karl T. The yin and yang of cannabis-induced psychosis: the actions of $(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Curr Pharm Des. 2012;18:5113-5130.
20. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35:764-774.
21. Hazekamp A, Bastola K, Rashidi H, et al. Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol. 2007;113:85-90.
22. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett. 2004;25:14-23.
23. Erkens JA, Janse AF, Herings RM. Limited use of medicinal cannabis but for labeled indications after legalization. Pharmacoepidemiol Drug Saf. 2005;14:821-822.
24. Gorter RW, Butorac M, Cobian EP, et al. Medical use of cannabis in the Netherlands. Neurology. 2005;64:917-919.
25. Folstein MF, Luria R. Reliability, validity, and clinical application of the visual analogue mood scale. Psychol Med. 1973;3:479-486.
26. Hart CL, Ward AS, Haney M, et al. Comparison of smoked marijuana and oral delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002;164:407-415.
27. Hart CL, van Gorp W, Haney M, et al. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001;25:757-765.
28. Huestis MA, Boyd SJ, Heishman SJ, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl). 2007;194:505-515.
29. Wachtel SR, ElSohly MA, Ross SA, et al. Comparison of the subjective effects of delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl). 2002;161:331-339.
30. Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16-21.
31. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6:713-737.
32. Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol. 2003; 2: 291-298.
33. Martín-Sánchez E, Furukawa TA, Taylor J, et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009;10:1353-1368.
34. Aggarwal SK, Carter GT, Sullivan MD, et al. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag. 2009;5:257-286.
35. Kumar RN, Kirking DM, Hass SL, et al. The association of consumer expectations, experiences and satisfaction with newly prescribed medications. Qual Life Res. 2007;16:1127-1136.
36. Crow R, Gage H, Hampson S, et al. The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature. Health Technol Assess. 2002;6:1-244.
37. Matthias P, Tashkin DP, Marques-Magallanes JA, et al. Effects of varying marijuana potency on deposition of tar and delta9-THC in the lung during smoking. Pharmacol Biochem Behav. 1997;58:1145-1150.
38. Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther. 2009;15:65-75.
39. Massi P, Solinas M, Cinquina V, et al. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013;75:303-312.
40. Ramer R, Bublitz K, Freimuth N, et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012;26:1535-1548.
41. Morgan CJ, Freeman TP, Schafer GL, et al. Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35:1879-1885.
42. van Laar M, van Dorsselaer S, Monshouwer K, et al. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction. 2007;102:1251-1260.
43. 1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci. 2005;26:609-617.
44. Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24:515-523.
45. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328.
46. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naBve social phobia patients. Neuropsychopharmacology. 2011;36:1219-1226.
47. Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther. 2002;95:185-190.
48. Nu.nl. Press release. More users use mediwiet. Available at: http://www.nu.nl/binnenland/2510922/steeds-meer-gebruikers-mediwiet.html. Accessed July 19, 2013.